Combination of a glycomimetic antagonist to E-selectin and CXCR4, GMI-1359, with an anti-PD-L1 antibody attenuates regulatory T Cell infiltration and accelerates time to complete response in the murine CT26 tumor model

Date: 2016

Authors: GlycoMimetics, Inc.: William E. Fogler, John L. Magnani; MI Bioresearch: Maryland Franklin, Matt Thayer, Dan Saims

Society for Immuno Therapy of Cancer (SITC)